Levonorgestrel intrauterine contraceptive systems (13.5 mg and 52 mg) and risk of ectopic pregnancy

被引:7
|
作者
Graner, Sofie [1 ,2 ]
Mc Taggart, Julia [3 ]
Nordstrom, Fanny [3 ]
Melander, Emma [3 ]
Widenberg, Johan [4 ]
Kallner, Helena Kopp [3 ,4 ,5 ]
机构
[1] Karolinska Inst, Karolinska Univ Hosp, Dept Med, Ctr Pharmacoepidemiol, Stockholm, Sweden
[2] Danderyd Hosp, Matern BB Stockholm, Stockholm, Sweden
[3] Karolinska Inst, Danderyd Hosp, Dept Clin Sci, Stockholm, Sweden
[4] Danderyd Hosp, Dept Obstet & Gynecol, Stockholm, Sweden
[5] Karolinska Inst, Dept Womens & Childrens Hlth, Stockholm, Sweden
关键词
Ectopic pregnancy; intrauterine contraception; levonorgestrel containing intrauterine system; levonorgestrel containing intrauterine system 13; 5; mg; levonorgestrel containing intrauterine system 52 mg; Pearl index; LNG-IUS; 8; PHASE-III; SINGLE-ARM; MULTICENTER; PROGESTASERT; SAFETY;
D O I
10.1111/aogs.13564
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Introduction The objective was to investigate the Pearl index for ectopic pregnancy in women using the levonorgestrel intrauterine system (LNG-IUS) at the time of conception. Material and methods This was a substudy of a hospital-based historical cohort including women with an ectopic pregnancy diagnosed in 4 referral hospitals in Stockholm, Sweden between December 2013 and April 2017. Study participants and type of contraception at time of conception were identified through the electronic medical chart system. Cases were defined as women with LNG-IUS 13.5 or 52 mg in situ at the time of diagnosis of ectopic pregnancy who had their LNG-IUS inserted 1 January 2014 or later. Outcome was defined as the incidence rate for ectopic pregnancy during use per 100 woman-years (Pearl index) with 95% confidence interval (95% CI). Results The study includes 35 cases with LNG-IUS 13.5 mg and 13 cases with LNG-IUS 52 mg, which occurred in 18 488 (13.5 mg) and 50 246 (52 mg) exposed woman-years. Pearl index for ectopic pregnancy was estimated at 0.19 (95% CI 0.15-0.28) for LNG-IUS 13.5 mg and to 0.006 (95% CI 0.00-0.01) for LNG-IUS 52 mg. The most cases for the LNG-IUS 13.5 mg (n = 26; 74%) occurred during the first year of use with a corresponding Pearl index at 0.23 (95% CI 0.14-0.35). Conclusions The absolute risk of ectopic pregnancy during the use of LNG-IUS remains low. Our method may underestimate as well as overestimate the Pearl index for ectopic pregnancy. The findings underline the importance of identifying risk factors for ectopic pregnancy at insertion, and to rule out ectopic pregnancy for all women presenting with abdominal discomfort during the use of LNG-IUS. Longer observation periods and prospective studies in a general population are a priority for further research.
引用
收藏
页码:937 / 943
页数:7
相关论文
共 50 条
  • [41] Clarification of the role of the Jaydess(Skyla) LNG- IUS 13.5mg and Kyleena LNG-IUS 19.5mg as intrauterine contraceptive systems
    Goldstuck, Norman D.
    EXPERT REVIEW OF MEDICAL DEVICES, 2017, 14 (08) : 593 - 599
  • [42] ECTOPIC PREGNANCY ASSOCIATED WITH THE INTRAUTERINE CONTRACEPTIVE DEVICE
    ALBUS, C
    ZENTRALBLATT FUR GYNAKOLOGIE, 1989, 111 (12): : 837 - 840
  • [43] Contraceptive Efficacy and Safety of 52 mg Levonorgestrel-Releasing Intrauterine Systems During Years 6-8 of Use: Data From the Mirena Extension Trial
    Jensen, Jeffrey T.
    OBSTETRICS AND GYNECOLOGY, 2022, 139 : 4S - 4S
  • [44] Consecutive Use of the 52 mg Levonorgestrel-releasing Intrauterine System: Variations in Bleeding Patterns
    Wittmann, Barbara Zantut
    Monteiro, Ilza
    Juliato, Cassia
    Fernandes, Arlete
    REVISTA BRASILEIRA DE GINECOLOGIA E OBSTETRICIA, 2020, 42 (04): : 194 - 199
  • [45] Levonorgestrel release rates over 5 years with the Liletta® 52-mg intrauterine system
    Creinin, Mitchell D.
    Jansen, Rolf
    Starr, Robert M.
    Gobburu, Joga
    Gopalakrishnan, Mathangi
    Olariu, Andrea
    CONTRACEPTION, 2016, 94 (04) : 353 - 356
  • [46] Postplacental intra-abdominal placement of levonorgestrel 52 mg intrauterine system: A case report
    Peterson, Sarah F.
    Henkel, Andrea
    Ganti, Amitha
    Blumenthal, Paul D.
    CONTRACEPTION, 2020, 101 (06) : 432 - 434
  • [47] Levonorgestrel 52 mg intrauterine system-(Levosert®)/Liletta®) in contraception: a profile of its use
    Lyseng-Williamson, Katherine A.
    DRUGS & THERAPY PERSPECTIVES, 2020, 36 (12) : 539 - 546
  • [48] Amenorrhea rates and predictors during 1 year of levonorgestrel 52 mg intrauterine system use
    Damey, Philip D.
    Stuart, Gretchen S.
    Thomas, Michael A.
    Cwiak, Carrie
    Olariu, Andrea
    Creinin, Mitchell D.
    CONTRACEPTION, 2018, 97 (03) : 210 - 214
  • [49] LEVONORGESTREL 52 MG INTRAUTERINE SYSTEM EFFICACY AND SAFETY THROUGH 8 YEARS OF USE.
    Creinin, Mitchell D.
    Schreiber, Courtney A.
    Turok, David K.
    Cwiak, Carrie
    Chen, Beatrice A.
    Olariu, Andrea I.
    FERTILITY AND STERILITY, 2021, 116 (03) : E472 - E473
  • [50] Experience with same-day placement of the 52 mg levonorgestrel-releasing intrauterine system
    Castano, Paula M.
    Westhoff, Carolyn L.
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2020, 222 (04)